hydrochlorothiazide has been researched along with canrenoic acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Karim, A | 1 |
| Fabiano, M; Marinelli, R; Morabito, S; Palumbo, R; Pierucci, A; Puliti, M; Simonetti, BM | 1 |
| Ambrosioni, E; Borghi, C; Costa, FV; Mussi, A | 1 |
| Bré, E; Corsico, G; Farinelli, F; Rampini, A; Regazzi, MB | 1 |
| De Croo, F; De Moerloose, P; Van den Bossche, W | 1 |
| Rahn, KH | 1 |
| Cusi, D; Glorioso, N; Madeddu, P; Manunta, P; Melis, MG; Pala, F; Pazzola, A; Soro, A; Tonolo, G; Troffa, C | 1 |
| Aubry, M; Girerd, N; Huttin, O; Lantelme, P; Rossignol, P | 1 |
1 review(s) available for hydrochlorothiazide and canrenoic acid
| Article | Year |
|---|---|
Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.
Topics: Animals; Biological Availability; Biotransformation; Canrenoic Acid; Drug Combinations; Erythrocytes; Food; Half-Life; Humans; Hydrochlorothiazide; Kinetics; Milk, Human; Protein Binding; Species Specificity; Spironolactone; Tissue Distribution | 1978 |
1 trial(s) available for hydrochlorothiazide and canrenoic acid
| Article | Year |
|---|---|
Different sensitivity to hydrochlorothiazide and to potassium-canrenoate among essential hypertensive patients.
Topics: Blood Pressure; Canrenoic Acid; Double-Blind Method; Drug Resistance; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium | 1993 |
6 other study(ies) available for hydrochlorothiazide and canrenoic acid
| Article | Year |
|---|---|
[Potassium canrenoate and the combination of potassium canrenoate-butizide in the therapy of light to moderate arterial hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Canrenoic Acid; Diuretics; Drug Evaluation; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Sodium Chloride Symporter Inhibitors | 1992 |
[Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
Topics: Adult; Canrenoic Acid; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Pregnadienes; Random Allocation; Sodium | 1988 |
[Evaluation of possible significant pharmacokinetic interactions between butizide and potassium canrenoate in man].
Topics: Adult; Canrenoic Acid; Diuretics; Drug Interactions; Humans; Hydrochlorothiazide; Male; Pregnadienes; Sodium Chloride Symporter Inhibitors | 1988 |
Simultaneous quantitative determination of butizide, potassium canrenoate and canrenone in tablets by high-performance liquid chromatography.
Topics: Canrenoic Acid; Canrenone; Chromatography, High Pressure Liquid; Diuretics; Drug Stability; Hydrochlorothiazide; Indicators and Reagents; Pregnadienes; Sodium Chloride Symporter Inhibitors; Spectrophotometry, Ultraviolet; Tablets | 1986 |
Clinical pharmacology of diuretics.
Topics: Canrenoic Acid; Canrenone; Diuretics; Ethacrynic Acid; Humans; Hydrochlorothiazide; Intestinal Absorption; Kinetics; Protein Binding; Sodium Chloride Symporter Inhibitors; Spironolactone | 1983 |
Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bumetanide; Canrenoic Acid; Creatinine; Diuresis; Diuretics; Drug Combinations; Drug Resistance; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Male; Mineralocorticoid Receptor Antagonists; Potassium; Treatment Outcome | 2021 |